Patent Highlights Improved Cefixime Formulation for Enhanced Bioavailability

The 2015 patent document sheds light on a pharmaceutical formulation of Cefixime, a semi-synthetic cephalosporin antibiotic widely used for oral administration. Cefixime is indicated for treating infections caused by both gram-positive and gram-negative organisms, including uncomplicated urinary tract infections (E. coli, P. mirabilis), otitis media (H. influenzae, M. catarrhalis, S. pyogenes), and respiratory infections such as acute bronchitis and exacerbations of chronic bronchitis caused by S. pneumoniae and H. influenzae.
The antibiotic is also approved for uncomplicated gonorrhea due to N. gonorrhoeae and remains one of the most commonly prescribed drugs in pediatric care. The patent focuses on improving Cefixime’s bioavailability, potentially enhancing its therapeutic efficacy and clinical outcomes.